- |||||||||| bortezomib / Generic mfg., melphalan / Generic mfg., thalidomide / Generic mfg.
Trial primary completion date: UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy (clinicaltrials.gov) - Sep 6, 2017 P3, N=177, Active, not recruiting, Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Aug 2017 --> Aug 2018
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Recurrent Meningioma of the Cervical Spine, Successfully Treated with Liposomal Doxorubicin. (Pubmed Central) - Sep 5, 2017 Our patient, a 35-year-old man with recurrent meningioma compressing the cervical spinal cord received liposomal doxorubicin for 22 months with clinical improvement, minimal toxicity, and slow regression of his tumor. He is well and without progression 18 months after stopping chemotherapy and 4 years after his last progression event.
- |||||||||| Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Trial primary completion date: Erythropoietin for Management of Anemia Caused by Chemotherapy (clinicaltrials.gov) - Sep 1, 2017 P2, N=53, Active, not recruiting, He is well and without progression 18 months after stopping chemotherapy and 4 years after his last progression event. Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. (Pubmed Central) - Aug 31, 2017 In addition, patients treated with R-CHOP experienced inferior 3-year RFS compared with those who received intensive front-line therapy. When considered in conjunction with reports of patients with newly diagnosed DHL, which demonstrate lower rates of disease response to R-CHOP compared with intensive front-line therapy, our findings further support the use of intensive front-line therapy for this patient population.
- |||||||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial primary completion date: Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma (clinicaltrials.gov) - Aug 30, 2017 P2, N=34, Active, not recruiting, When considered in conjunction with reports of patients with newly diagnosed DHL, which demonstrate lower rates of disease response to R-CHOP compared with intensive front-line therapy, our findings further support the use of intensive front-line therapy for this patient population. Trial primary completion date: Jan 2017 --> Jan 2015
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date, Metastases: MC078E: Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma (clinicaltrials.gov) - Aug 29, 2017 P1/2, N=47, Recruiting, Efficacy was observed in multiple tumour types and evaluation to determine if response and duration of response are more robust than what would be expected for chemotherapy or immunotherapy alone requires further validation. Trial primary completion date: May 2017 --> May 2018
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed, Trial primary completion date: Study in Patients With Primary Breast Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Aug 29, 2017 P2, N=33, Active, not recruiting, Trial primary completion date: May 2017 --> May 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> Aug 2019
- |||||||||| Rituxan (rituximab) / Roche
Trial completion, Trial primary completion date, IO biomarker, Metastases: Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients (clinicaltrials.gov) - Aug 28, 2017 P3, N=210, Completed, Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2018 --> Aug 2017
- |||||||||| Campath (alemtuzumab) / Sanofi, Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial initiation date: Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System (clinicaltrials.gov) - Aug 24, 2017 P2, N=92, Active, not recruiting, Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Aug 2016; Enrollment Completed Initiation date: Jul 2007 --> Oct 2007
- |||||||||| cisplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Trial primary completion date: Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer (clinicaltrials.gov) - Aug 24, 2017 P1, N=27, Completed, Initiation date: Jul 2007 --> Oct 2007 Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jul 2016
- |||||||||| doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed, Trial primary completion date, Surgery: GOG study : Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery (clinicaltrials.gov) - Aug 24, 2017 P3, N=216, Active, not recruiting, Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jul 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2018 --> Jun 2018
- |||||||||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: Trabectedin Maintenance Post 1st-line in STS (clinicaltrials.gov) - Aug 24, 2017 P3, N=90, Recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2018 --> Jun 2018 Not yet recruiting --> Recruiting | Initiation date: Apr 2017 --> Aug 2017 | Trial primary completion date: Apr 2019 --> Aug 2019
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, pomalidomide / Generic mfg.
Journal: Kaposi sarcoma herpesvirus-associated disorders and related diseases. (Pubmed Central) - Aug 23, 2017 KSHV is the etiological agents of all forms of Kaposi sarcoma and several other diseases. Strategies employing immunomodulatory agents, cytokine inhibition, and targeting of KSHV-infected cells are areas of active research.
- |||||||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Trial completion, Combination therapy, Metastases: Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors (clinicaltrials.gov) - Aug 23, 2017 P1, N=122, Completed, Strategies employing immunomodulatory agents, cytokine inhibition, and targeting of KSHV-infected cells are areas of active research. Active, not recruiting --> Completed
- |||||||||| prednisone / Generic mfg., doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg.
Journal: Angioimmunoblastic T-cell lymphoma: the many faced lymphoma. (Pubmed Central) - Aug 23, 2017 The treatment of relapsed or refractory AITL remains an unmet need. The spectrum of AITL from diagnosis to treatment is reviewed below in a fashion that may one day lead to personalized treatment approach in a many faced disease.
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Phase classification: A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma (clinicaltrials.gov) - Aug 22, 2017 P1b, N=33, Completed, N=480 --> 360 | Trial primary completion date: Jun 2017 --> May 2015 Phase classification: P1 --> P1b
- |||||||||| Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment open: Chidamide With R-CHOP Regimen for DLBCL Patients (clinicaltrials.gov) - Aug 22, 2017 P2, N=39, Recruiting, Recruiting --> Suspended Not yet recruiting --> Recruiting
- |||||||||| Herceptin (trastuzumab) / Roche
Biomarker, Journal: Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer. (Pubmed Central) - Aug 18, 2017 In breast cancer patients undergoing doxorubicin therapy, early alterations in arginine-NO metabolite levels occurred, and early biomarker changes were associated with a greater CTRCD rate. Our findings highlight the potential mechanistic and translational relevance of this pathway to CTRCD.
- |||||||||| oxaliplatin / Generic mfg., cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Trial primary completion date: Treating Peritoneal Carcinomatosis With PIPAC (clinicaltrials.gov) - Aug 16, 2017 P2, N=35, Completed, Cancer 2017;123:1810-1816. Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Aug 2017
|